Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950039 · ClinicalTrials.gov registry record · Phase 2
Metabolic Effects of Betaine Supplementation
A Phase 2 study of Obesity and Dysglycemia, sponsored by Joslin Diabetes Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01950039: Completed Phase 2 study of Obesity and Dysglycemia, sponsored by Joslin Diabetes Center.
NCT01950039 is a Phase 2 study of Obesity and Dysglycemia that has completed, run by Joslin Diabetes Center. The registered enrollment target is 28 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01950039, a Phase 2 study of Obesity and Dysglycemia, has completed, sponsored by Joslin Diabetes Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Betaine is important in cellular metabolic pathways. Few epidemiologic studies link betaine levels to diabetes and cardiovascular disease. Small human studies suggest benefit for non-alcoholic liver disease. In this study we will determine if administration of betaine improves metabolic measures, liver fat and/or endothelial function in humans with glucose intolerance who are overweight.
Primary Outcome
Glucose levels were analyzed in the fasting state and two hours after glucose load, comparing baseline to 12 weeks.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Betaine
Study Locations (1)
Massachusetts
- Joslin Diabetes Center and Brigham and Womens Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2014-01 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
What the finished NCT01950039 record still lists
NCT01950039 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01950039 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01950039 about?
NCT01950039 is a clinical study titled "Metabolic Effects of Betaine Supplementation". Betaine is important in cellular metabolic pathways. Few epidemiologic studies link betaine levels to diabetes and cardiovascular disease. Small human studies suggest benefit for non-alcoholic liver disease. In this study we will determine if administration of betaine improves metabolic measures, li...
What is the current status of trial NCT01950039?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2014-01. Estimated completion is 2018-08.
What conditions does trial NCT01950039 study?
This clinical trial studies the following conditions: Obesity, Dysglycemia.
What interventions are being tested in trial NCT01950039?
The interventions under investigation include: Placebo (DRUG), Betaine (DRUG).
Who is sponsoring clinical trial NCT01950039?
This trial is sponsored by Joslin Diabetes Center, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01950039 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01950039's enrollment target sits among peer trials
28 886th of 1053 higher than 162 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia